Icon Plc (ICLR) Receives Average Recommendation of “Buy” from Analysts

Share on StockTwits

Icon Plc (NASDAQ:ICLR) has received an average rating of “Buy” from the eleven analysts that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $149.00.

A number of research analysts have issued reports on the company. BidaskClub upgraded Icon from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. UBS Group assumed coverage on Icon in a research note on Tuesday, October 9th. They issued a “sell” rating and a $145.00 price objective for the company. KeyCorp upped their price objective on Icon from $152.00 to $157.00 and gave the company an “overweight” rating in a research note on Tuesday, September 11th. Robert W. Baird upped their price objective on Icon from $154.00 to $157.00 and gave the company an “outperform” rating in a research note on Tuesday, September 11th. Finally, Zacks Investment Research upgraded Icon from a “hold” rating to a “buy” rating and set a $163.00 price objective for the company in a research note on Thursday, August 9th.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Marietta Investment Partners LLC lifted its position in shares of Icon by 18.3% during the 2nd quarter. Marietta Investment Partners LLC now owns 2,472 shares of the medical research company’s stock valued at $328,000 after buying an additional 382 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Icon by 1.9% during the 2nd quarter. Fisher Asset Management LLC now owns 21,316 shares of the medical research company’s stock valued at $2,825,000 after buying an additional 400 shares during the last quarter. Cambiar Investors LLC lifted its position in shares of Icon by 9.9% during the 2nd quarter. Cambiar Investors LLC now owns 4,498 shares of the medical research company’s stock valued at $596,000 after buying an additional 405 shares during the last quarter. CIBC Private Wealth Group LLC lifted its position in shares of Icon by 0.5% during the 2nd quarter. CIBC Private Wealth Group LLC now owns 80,342 shares of the medical research company’s stock valued at $10,648,000 after buying an additional 405 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in shares of Icon by 119.7% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 769 shares of the medical research company’s stock valued at $113,000 after buying an additional 419 shares during the last quarter. 87.62% of the stock is currently owned by hedge funds and other institutional investors.

Icon stock traded down $0.67 during trading on Monday, hitting $138.46. 155,402 shares of the company were exchanged, compared to its average volume of 260,155. The company has a market capitalization of $7.77 billion, a P/E ratio of 25.69, a price-to-earnings-growth ratio of 2.06 and a beta of 0.50. The company has a current ratio of 2.17, a quick ratio of 2.17 and a debt-to-equity ratio of 0.26. Icon has a 52 week low of $101.22 and a 52 week high of $155.33.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, October 24th. The medical research company reported $1.54 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.54. The firm had revenue of $655.02 million during the quarter, compared to the consensus estimate of $654.66 million. Icon had a return on equity of 26.08% and a net margin of 12.88%. On average, analysts predict that Icon will post 6.08 EPS for the current year.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Article: Trading Strategy

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply